VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RDY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RDYDr. Reddy's Laboratories Limited
$14.98$12.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
RDY logo

Dr. Reddy's Laboratories Limited

RDY
NYSE · Specialty & Generic Drugs
$14.98
At close - Nov 18, 4:00 PM EST - USD
Market Cap$12.47B
P/E41.6x
52W High$15.67
Volume1.65M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2027Q2

Margin Erosion, Cash Conversion Woes Cloud Dr. Reddy's Outlook

Dr. Reddy's appears to be at an inflection point where a growth portfolio built on acquisitions and heavy capital investment is colliding with structural US generics pricing pressure, as evidenced by 2027Q2 revenue declining 1.7% year-over-year to $86.6B and gross margin compressing roughly 830 basis points from 60.4%…

GrowthDecelerating
ProfitabilityStrained
ValuationAttractive
TechnicalsNeutral
Explore valuation models
MARKET ACTION

RDY price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

+10% Peers

P/E is 10% above peer median

03

Market leadership

RS 79 · Avg

Average momentum (RS Rating: 79)

04

Trend Check

N/A

Trend data unavailable

Next CatalystEstimated earnings · Jan 23
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue contracted 1.7% year-over-year to $86.6B in 2027Q2 while operating margin fell to 13.7% from 23.4% in 2025Q1, reflecting approximately 830 basis points of gross margin compression (60.4% to 52.1%) and negative operating leverage as SG&A held near $27-29B against a shrinking gross profit base.

Analyst Consensus-4.2% target
Buy(12 analysts)
6 Buy4 Hold2 Sell

The Bull Case

Upside Catalysts

Strong share price target

Analyst consensus projects a bullish share price target of Rs 1,800-2,000 for 2026, indicating significant upside potential.

Attractive valuation metrics

Trading at 18x P/E with a market cap of Rs 96,000 Cr, the stock presents a compelling valuation case for long-term investors.

Global pharmaceutical presence

As a global player with diverse offerings including generics and APIs, Dr. Reddy's benefits from a wide market reach and product diversification.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
RDY+9.15%
S&P 500 (^GSPC)+6.88%
1-Year Return
RDY+7.90%
S&P 500 (^GSPC)+10.62%
3-Year Return
RDY+13.33%
S&P 500 (^GSPC)+61.26%
5-Year Return
RDY+24.58%
S&P 500 (^GSPC)+59.30%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
41.6x
Forward P/EExpansion
0.2x
EV/EBITDA100th %ile
24.0x
FCF YieldCash Flow
1.0%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
41.6x
0.2x
100th· High
EV/EBITDA
24.0x
0.5x
100th· High
Price/FCF
97.1x
0.7x
100th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$7.84-47.7%
Base (Fair)$13.22-10.3%
Bull$19.46+29.9%
$7.84 Bear$13.22 Base$19.46 Bull
Current Market Price: $14.98
Trades at a 13.3% premium to Base DCF ($13.22)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY26
$353.47B+8.6% YoY
Net income FY26
$45.09B-20.3% YoY
Free cash flow FY26
$32.1B+166.8% YoY
Operating margin FY26
13.8%-8.2 pts YoY
ROIC (FY26)9.1%
Avg ROIC 5Y16.9%
ROE (TTM)7.3%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 23, 2026
$0.12+24.0%
vs $0.10
$911M+1.8%
vs $895M
Q3 2026
Jul 21, 2026
$0.06-34.7%
vs $0.09
$836M-1.7%
vs $851M
Q2 2026
May 11, 2026
$0.06-33.3%
vs $0.09
$786M-11.4%
vs $887M
Q1 2026
Jan 20, 2026
$0.16+0.0%
vs $0.16
$952M+2.6%
vs $928M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·Oct 26, 2026
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall

Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.

The Motley Fool·Oct 25, 2026
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors

Semaglutide supply reloading will begin by November 2026. Base business revenue grew double digits excluding North American Lenalidomide.

Seeking Alpha·Oct 23, 2026
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript

MarketBeat·Oct 23, 2026
Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business.

Filtered for Dr. Reddy's Laboratories LimitedMore Headlines
04

Compare before deciding

Benchmark RDY against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Dr. Reddy's Laboratories Limited (RDY)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
RDY logoRDYDr. Reddy's Laboratories LimitedCurrent
$14.98$12.47B41.648.58%8.46%7.35%0.6%
SUN logoSUNSunoco LP
$61.73$8.44B2128.6211.05%2.9%18.07%7.76%
PRGO logoPRGOPerrigo Company plc
$16.94$2.34B-1.33-2.75%-43.27%-68.13%6.79%
AMRX logoAMRXAmneal Pharmaceuticals, Inc.
$21.88$6.99B49.788.05%4.62%82.23%—
TEVA logoTEVATeva Pharmaceutical Industries Limited
$42.23$49.96B98.744.31%2.94%6.35%—
VTRS logoVTRSViatris Inc.
$20.28$23.62B-38.32-2.98%-4.13%-4.24%2.36%

Compare RDY vs Peers

Dr. Reddy's Laboratories Limited (RDY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SUN

Most directly comparable listed peer for RDY.

Scale Benchmark

vs LLY

Larger-name benchmark to compare RDY against a more recognizable public peer.

Peer Set

Compare Top 5

vs SUN, PRGO, AMRX, TEVA

Get notified when RDY posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

RDY Frequently Asked Questions

Dr. Reddy's Laboratories Limited (RDY) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Dr. Reddy's Laboratories Limited's revenue?

Dr. Reddy's Laboratories Limited (RDY) reported $331.38B in revenue over the trailing twelve months. Revenue was $353.47B in fiscal year 2026. That is 3132% more than the $10.94B of fiscal year 2001.

How fast is Dr. Reddy's Laboratories Limited growing?

Dr. Reddy's Laboratories Limited (RDY) revenue fell by 3.1% over the trailing twelve months, compared with the twelve months before.

Is RDY profitable?

Yes. Dr. Reddy's Laboratories Limited (RDY) earned $28.03B in net income over the trailing twelve months (a 8.5% net margin).

Dividend & Returns
Does RDY pay dividends?

Yes. Dr. Reddy's Laboratories Limited (RDY) pays a dividend that yields 0.60% at the current price, a small yield.

What is RDY's return on equity?

Dr. Reddy's Laboratories Limited (RDY) had a return on equity (ROE) of 7.3% over the trailing twelve months. That is below the market's typical 10-15%.

What is Dr. Reddy's Laboratories Limited's free cash flow?

Dr. Reddy's Laboratories Limited (RDY) generated $12.01B in free cash flow over the trailing twelve months.

What if you invested $1,000 in RDY back in 2001?

Total return calculator · dividends reinvested · 25+ years of data

See returns →